0113 QT Deals
BioCentury & Getty Images


Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

Jan 14, 2021 | 1:18 AM GMT

KSQ Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exclusive, global rights to develop, manufacture and commercialize cell and non-cell therapies that modulate targets identified with KSQ's CRISPRomics platform. The deal includes up to four T cell targets, two of which KSQ already validated,

Read the full 721 word article

How to gain access

Continue reading with a
two-week free trial.